drugset / Trial / NCT00492232

Facilitation of Zolpidem (≥10 mg) Discontinuation Through Use of Ramelteon in Subjects With Chronic Insomnia

NCT00492232

Phase 4 Completed 135 enrolled Takeda
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess whether ramelteon, once daily (QD), can facilitate the discontinuation of zolpidem in subjects with chronic insomnia.

Timeline

Start
2007-04
Primary completion
2008-03
Completion
2008-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Ramelteon Unknown 8 mg Oral
Subject Zolpidem Small molecule

Indications